Genix Announces Change of Auditor

Vancouver, British Columbia, November 10, 2022 – Genix Pharmaceuticals Corporation (TSXV:

GENX; OTCQB: GENPF) (“GENIX” or the “Company”) announces that it has appointed Buckley

Dodds CPA (“Successor Auditor”) as the Company’s auditor, replacing Harbourside CPA, LLP

(“Former Auditor”).

The Board of Directors accepted the resignation of the Former Auditor of the Company effective

August 25, 2022. There were no reportable events, disagreements, or unresolved issues (as those

terms defined by Part 4.11 of National Instrument 51-102 – Continuous Disclosure Obligations)

between the Company and the Former Auditor.

The Audit Committee and Board of Directors have appointed the Successor Auditor as the

Company’s auditor effective November 4, 2022, until the next annual meeting of shareholders.

In accordance with National Instrument 51-102, the Notice of Change of Auditor, together with

the required letters from the Former Auditor and the Successor Auditor, have been reviewed by

the Company’s Audit Committee and will be filed on SEDAR accordingly.

About Genix

Genix Pharmaceuticals Corporation is a novel nutraceutical and generic ophthalmic drugs

company. The Company is focused on the research, development, manufacture, licencing and

sales of innovative healthcare products. In particular, these products include evidence-based,

proprietary over-the-counter (“OTC”) nutraceuticals, and other single molecule generic drugs

that have been shown to deliver consistent and verifiable results in various therapeutic areas.

The Company will market and sell its nutraceutical products in North America and select

countries. Genix will also begin to market and sell its generic drugs in Canada upon receiving

Health Canada approvals. Genix continues to conduct scientific R&D of new and innovative

products to support the health needs of mainstream consumers.

On Behalf of the Board of Directors,

“Mahmoud Aziz”

Mr. Mahmoud Aziz

President, Director

Genix Pharmaceuticals Corporation

2 of 2

For more information regarding Genix Pharmaceuticals Corporation, please contact:

Kevin Bottomley, Director

Tel: +1.604.609.6199

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined

in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or

accuracy of this release.

Cautionary Note Regarding Forward Looking Statements: This release contains forward-looking

statements that involve risks and uncertainties. These statements may differ materially from actual future

events or results and are based on current expectations or beliefs. For this purpose, statements of historical

fact may be deemed to be forward-looking statements. In addition, forward-looking statements include

statements in which the Company uses words such as “continue”, “efforts”, “expect”, “believe”,

“anticipate”, “confident”, “intend”, “strategy”, “plan”, “will”, “estimate”, “project”, “goal”, “target”,

“prospects”, “optimistic” or similar expressions. These statements by their nature involve risks and

uncertainties, and actual results may differ materially depending on a variety of important factors,

including, among others, the Company’s ability and continuation of efforts to timely and completely make

available adequate current public information, additional or different regulatory and legal requirements

and restrictions that may be imposed, and other factors as may be discussed in the documents filed by the

Company on SEDAR (, including the most recent reports that identify important risk

factors that could cause actual results to differ from those contained in the forward-looking statements.

The Company does not undertake any obligation to review or confirm analysts’ expectations or estimates

or to release publicly any revisions to any forward-looking statements to reflect events or circumstances

after the date hereof or to reflect the occurrence of unanticipated events. Investors should not place undue

reliance on forward-looking statements

Previous Post
Genix Announces Auditor Resignation
Next Post
Genix Announces AGM Results

Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.
You need to agree with the terms to proceed